Head-to-head · Cost-Efficiency Index
boostAGErx vs Claya
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
boostAGErx
Cost-sensitive shoppers prepaying 12 months for low-cost GLP-1.
Visit boostAGErxClaya
Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Visit ClayaThe verdict
boostAGErx and Claya tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with boostAGErx (ranked #96, a hair above #97) — Cost-sensitive shoppers prepaying 12 months for low-cost GLP-1. But Claya is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs boostAGErx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | boostAGErx | Claya |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $95/mo (billed every 28 days, compounded) | $149/mo (all doses, compounded) |
| Tirzepatide / mo | $145/mo (billed every 28 days, compounded) | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,140 | $1,788 |
| Tirzepatide / yr (modeled) | $1,740 | $2,388 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #96 | #97 |
boostAGErx
69/100Where the value is
- Compounded GLP-1 starting around $95/mo (12-month plan paid upfront)
- Free shipping and clinical evaluation included
- Membership fee refunded in full if you're not approved
The tradeoffs
- Billing runs on a 28-day cycle rather than a calendar month — thirteen charges a year, so the $145 tirzepatide rate is $1,885 a year, an effective $157/mo
- The terms call the charge a 'membership fee' while the marketing carousel says 'No Membership Fees Ever'
Claya
69/100Where the value is
- Semaglutide is explicitly 'same price regardless of dosage' at $149/mo, removing dose-tier guesswork
- LegitScript Certified, BBB Accredited, and HIPAA Compliant badges all displayed together
- '$100 off your first month' promo code (100CLAYA) published openly with no intake required to see it
The tradeoffs
- The advertised $149/$199 rates are qualified elsewhere on the same page as available 'with select multi-month plans' — a shopper reading only the 'a month' headline could reasonably assume pure month-to-month billing when a prepay term may be required
- No state coverage list is published anywhere on the public site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.